Literature DB >> 6696172

Long term follow-up of human hydatid disease (Echinococcus granulosus) treated with a high-dose mebendazole regimen.

W S Kammerer, P M Schantz.   

Abstract

Fifteen patients with inoperable hydatid disease (Echinococcus granulosus) were treated with an initial 6-week high-dose mebendazole regimen with a follow-up ranging from 3-7 years. Ten of 15 patients showed both objective and clinical improvement, although two of these 10 relapsed 1-6 years after completing therapy. Simple, single cysts in the lung and liver showed the best response. Multiple, complex cysts and bone cysts showed little or no objective improvement. One patient developed reversible neutropenia. Overall results were no better than those obtained by others with smaller doses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696172     DOI: 10.4269/ajtmh.1984.33.132

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  New aspects in the management of alveolar echinococcosis involving the liver.

Authors:  R Schröder; G Robotti
Journal:  World J Surg       Date:  1986-12       Impact factor: 3.352

2.  Serology in patients treated with albendazole for hydatid disease.

Authors:  M H Wilcox; D L Morris; J W Bailey
Journal:  J R Soc Med       Date:  1988-12       Impact factor: 5.344

3.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

Review 4.  Diagnosis and treatment of human hydatidosis.

Authors:  H Wen; R R New; P S Craig
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

5.  Factors influencing the response to chemotherapy in human cystic echinococcosis.

Authors:  T Todorov; G Mechkov; K Vutova; P Georgiev; I Lazarova; Z Tonchev; G Nedelkov
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

Review 6.  Treatment of hydatid disease.

Authors:  D Anadol; U Ozçelik; N Kiper; A Göçmen
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

Review 8.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

9.  Therapy of human hydatid disease with mebendazole and albendazole.

Authors:  A Teggi; M G Lastilla; F De Rosa
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial.

Authors:  Gary L Gallia; Matthias Holdhoff; Henry Brem; Avadhut D Joshi; Christine L Hann; Ren-Yuan Bai; Verena Staedtke; Jaishri O Blakeley; Soma Sengupta; T Che Jarrell; Jessica Wollett; Kelly Szajna; Nicole Helie; Austin K Mattox; Xiaobu Ye; Michelle A Rudek; Gregory J Riggins
Journal:  Neurooncol Adv       Date:  2020-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.